Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects
Authors:
- 7 May 2013
- journal article
- Published by Springer Nature in Psychopharmacology
- Vol. 229 (2) , 245-252
Abstract
A positron emission tomography (PET) study of dopamine D2 receptor occupancy was conducted to support a rational dose selection for clinical efficacy studies with lurasidone, an atypical antipsychotic that was approved for the treatment of schizophrenia by the FDA in late 2010. To determine the dopamine D2 receptor occupancy of lurasidone in the ventral striatum, putamen and caudate nucleus, and to characterize the relationship between lurasidone serum concentration and D2 receptor occupancy. A single oral dose of lurasidone (10, 20, 40, 60, or 80 mg) was administered sequentially to healthy male subjects (n = 4 in each cohort). Two PET scans were performed. For each scan, 20 mCi of [11C]raclopride was administered intravenously as a bolus injection, followed immediately by 90 min of PET scan acquisitions. The D2 receptor occupancy levels were 41–43 % for 10 mg, 51–55 % for 20 mg, 63–67 % for 40 mg, 77–84 % for 60 mg, and 73–79 % for 80 mg of lurasidone. The relationship between D2 receptor occupancy and the mean serum lurasidone concentration during the PET scan (C PET) was similar for the putamen, caudate nucleus, and ventral striatum regions. Mean D2 receptor occupancy levels correlated well with average peak serum concentration of lurasidone. In healthy volunteers, single doses of lurasidone 40–80 mg resulted in D2 receptor occupancy levels of >60 %, a level of receptor occupancy previously associated with clinical response for atypical antipsychotics.Keywords
This publication has 32 references indexed in Scilit:
- Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority studySchizophrenia Research, 2013
- Dopamine D2 Receptor Occupancy and Clinical EffectsJournal of Clinical Psychopharmacology, 2011
- Prediction of Repeat-Dose Occupancy from Single-Dose Data: Characterisation of the Relationship between Plasma Pharmacokinetics and Brain Target OccupancyJournal of Cerebral Blood Flow & Metabolism, 2010
- Lurasidone in the Treatment of Acute SchizophreniaThe Journal of Clinical Psychiatry, 2009
- Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of ZiprasidoneJournal of Clinical Psychopharmacology, 2008
- Quetiapine Extended-Release Versus Immediate-Release FormulationThe Journal of Clinical Psychiatry, 2008
- Consensus Nomenclature for in vivo Imaging of Reversibly Binding RadioligandsJournal of Cerebral Blood Flow & Metabolism, 2007
- Relationships Among Ventral Striatal Dopamine Release, Cortisol Secretion, and Subjective Responses to AmphetamineNeuropsychopharmacology, 2005
- Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory RegionBiochemical and Biophysical Research Communications, 1999
- Preparation of 11C-labelled raclopride, a new potent dopamine receptor antagonist: Preliminary PET studies of cerebral dopamine receptors in the monkeyThe International Journal of Applied Radiation and Isotopes, 1985